🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

212 results for “Bristol-Myers” Clear

  1. Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL

    Bristol-Myers Squibb / Pfizer EEIG

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  2. Placebo 15mg Tablets, Placebo 6mg tablets, venglustat GZ402671 - SAR402671, venglustat GZ402671 - SAR402671

    Sanofi Pharma Bristol-Myers Squibb

    Fabry Disease

    phase 3 small molecule active

    1 trial

  3. Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  4. Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  5. Prograft 5 mg capsules, hard, Prograf 0,5 mg Hartkapseln, Prograf 1 mg Hartkapseln, Frexalimab, Prograft 0,5 mg capsules, hard, Prograft 1 mg capsules, hard, Prograf 5 mg Hartkapseln

    Sanofi Pharma Bristol-Myers Squibb

    Kidney transplant rejection

    phase 3 small molecule active

    1 trial

  6. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi Pharma Bristol-Myers Squibb

    multiple sclerosis

    phase 3 other active

    1 trial

  7. Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

    Sanofi Pharma Bristol-Myers Squibb

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  8. Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa

    Sanofi Pharma Bristol-Myers Squibb

    Plasma cell myeloma

    phase 3 small molecule active

    1 trial

  9. Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 3 small molecule active

    1 trial

  10. Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  11. SAR439774, SAR439774

    Sanofi Pharma Bristol-Myers Squibb

    Hemophilia

    phase 3 small molecule active

    1 trial

  12. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Blood and lymphatic diseases

    phase 3 small molecule active

    1 trial

  13. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  14. Teplizumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  15. Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)

    Sanofi Pharma Bristol-Myers Squibb

    Pneumococcal Immunization

    phase 3 small molecule active

    1 trial

  16. XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

    Bristol-Myers Squibb / Pfizer EEIG

    Non small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb / Pfizer EEIG

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  18. deucravacitinib, Placebo to match BMS 986165 tablet

    Bristol-Myers Squibb / Pfizer EEIG

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  19. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb / Pfizer EEIG

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  20. deucravacitinib, Placebo to match deucravacitinib tablet

    Bristol-Myers Squibb / Pfizer EEIG

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  21. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb / Pfizer EEIG

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  22. matched placebo for test product, Duvakitug

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  23. riliprubart

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases.

    phase 3 small molecule active

    1 trial

  24. riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

    Sanofi Pharma Bristol-Myers Squibb

    Polyneuropathy, Inflammatory Demyelinating, Chronic

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources